Bedfont®, a world leader in breath analysis, has been recognized as one of Investec Direct Lending’s selected investments for 2025 following Keensight Capital’s majority investment in the company. The inclusion highlights Bedfont’s position as a leading UK medical technology innovator and reflects confidence from both Keensight and Investec in the company’s long-term growth strategy.
Why is this important?
Being featured in Investec Direct Lending’s Sustainability Report reflects confidence in Bedfont’s long-term growth and responsible approach to innovation. With a vision of a world where everyone has access to instant, non-invasive breath testing to aid medical diagnosis, Bedfont® continues to develop technologies that improve patient care while supporting a more sustainable future for healthcare. The investment from Keensight provides a strong foundation for the company’s continued innovation, international expansion and long-term sustainable growth.
For more than 50 years, Bedfont® has worked with healthcare professionals worldwide to deliver high-quality breath analysis solutions through technical innovation and professional business practices. Today, its products continue to support improved patient care across global healthcare markets, reinforcing Bedfont’s reputation as a trusted leader in non-invasive breath analysis.
Looking ahead.
The recognition also aligns with Bedfont’s commitment to responsible business practices, combining innovation with a long-term focus on improving patient outcomes, supporting its people and operating sustainably as the company continues to grow. As Bedfont® looks to the future, the company remains committed to advancing innovative, sustainable healthcare solutions and building on its successful portfolio of breath analysis devices. With Keensight’s support, Bedfont® is well positioned to continue its growth journey and expand its impact on patient care worldwide.
Bedfont® Scientific Limited partners with Rymindr to deliver vital classroom supplies